A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.

[1]  A. Pathare,et al.  Comparative Assessment of Deferiprone and Deferasirox in Thalassemia Major Patients in the First Two Decades-Single Centre Experience , 2013, Pediatric hematology and oncology.

[2]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[3]  P. Fenaux,et al.  Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes , 2012, Haematologica.

[4]  T. Ganz,et al.  Iron metabolism: interactions with normal and disordered erythropoiesis. , 2012, Cold Spring Harbor perspectives in medicine.

[5]  D. Steensma.  The Relevance of Iron Overload and the Appropriateness of Iron Chelation Therapy for Patients with Myelodysplastic Syndromes: A Dialogue and Debate , 2011, Current hematologic malignancy reports.

[6]  H. Leitch.  Controversies surrounding iron chelation therapy for MDS. , 2011, Blood reviews.

[7]  A. Ganser,et al.  Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. , 2010, Leukemia research.

[8]  A. Stamatoullas,et al.  Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies). , 2010, Leukemia research.

[9]  N. Gattermann,et al.  Iron overload in MDS—pathophysiology, diagnosis, and complications , 2010, Annals of Hematology.

[10]  D. Mikulenková,et al.  Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts. , 2009, Leukemia research.

[11]  L. Arenillas,et al.  Independent Impact of Iron Overload and Transfusion Dependency on Survival and Leukemic Evolution in Patients with Myelodysplastic Syndrome , 2008 .

[12]  M. Cazzola,et al.  Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study , 2007, European journal of haematology.

[13]  M. Cazzola,et al.  Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Armand,et al.  Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. , 2007, Blood.

[15]  S. Perrotta,et al.  A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. , 2006, Blood.

[16]  E. Neufeld.  Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. , 2006, Blood.

[17]  J. Čermák.  Erythropoietin Administration May Potentiate Mobilization of Storage Iron in Patients on Oral Iron Chelation Therapy , 2006, Hemoglobin.

[18]  Luca Malcovati,et al.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  D. Pennell,et al.  Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance , 2004, British journal of haematology.

[20]  G. Mufti,et al.  Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes , 2003, British journal of haematology.

[21]  D. Bowen,et al.  Best supportive care for the anaemia of myelodysplasia: inclusion of recombinant erythropoietin therapy? , 2001, Leukemia research.

[22]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[23]  B. S. van Asbeck,et al.  Use of iron chelators in preventing hydroxyl radical damage: adult respiratory distress syndrome as an experimental model for the pathophysiology and treatment of oxygen-radical-mediated tissue damage. , 1996, Acta haematologica.

[24]  G. Koren,et al.  Iron-chelation therapy with oral deferiprone in patients with thalassemia major. , 1995, The New England journal of medicine.

[25]  A. Hoffbrand,et al.  Deferiprone‐associated myelotoxicity , 1994, European journal of haematology.

[26]  A. Hoffbrand,et al.  1,2-DIMETHYL-3-HYDROXYPYRID-4-ONE, AN ORALLY ACTIVE CHELATOR FOR TREATMENT OF IRON OVERLOAD , 1987, The Lancet.